Pancreatic cancer is one of the deadliest of all cancers. Only 12 per cent of men diagnosed with pancreatic cancer are alive five years after diagnosis; for women it is 14 per cent.
Ajay Goel, PhD, AGAF, discusses how the development and validation of novel non-invasive biomarkers can improve early detection and ultimately impact patient outcomes for patients.